2.45BMarket Cap
LossP/E TTM
Ultragenyx Pharmaceutical Inc
Key Figures
25.950Open
26.075High
1.54MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.56%Turnover Ratio
26.040Prev. Close
24.595Low
30.08MTurnover
LossP/E Static
-10.38P/B
0.00%Div Yield TTM
-46.70%ROA
42.37052wk High
0.76Volume Ratio
-569.18MNet Profit
98.30MShares
-6.1016EPS TTM
0.26Beta
-656.03%ROE
18.29052wk Low
5.68%Amplitude
77.94%Gross Margin
2.45BMarket Cap
-7.60Reward/Risk
2.99%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 52.06.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ultragenyx Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Ultragenyx Pharmaceutical Inc Highlights
StrengthsRisks
Ultragenyx Pharmaceutical Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ultragenyx Pharmaceutical Inc
RARE
19
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ultragenyx Pharmaceutical Inc Info
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ticker SymbolRARE
CompanyUltragenyx Pharmaceutical Inc
CEOKakkis (Emil D)
Websitehttps://www.ultragenyx.com/
Shareholders
FAQs
What is the current price of Ultragenyx Pharmaceutical Inc (RARE)?
The current price of Ultragenyx Pharmaceutical Inc (RARE) is 24.91.
What is the symbol of Ultragenyx Pharmaceutical Inc?
The ticker symbol of Ultragenyx Pharmaceutical Inc is RARE.
What is the 52-week high of Ultragenyx Pharmaceutical Inc?
The 52-week high of Ultragenyx Pharmaceutical Inc is 42.37.
What is the 52-week low of Ultragenyx Pharmaceutical Inc?
The 52-week low of Ultragenyx Pharmaceutical Inc is 18.29.
What is the market capitalization of Ultragenyx Pharmaceutical Inc?
The market capitalization of Ultragenyx Pharmaceutical Inc is 2.45B.
Is Ultragenyx Pharmaceutical Inc (RARE) currently rated as Buy, Hold, or Sell?
According to analysts, Ultragenyx Pharmaceutical Inc (RARE) has an overall rating of Buy, with a price target of 52.06.
What is the Earnings Per Share (EPS TTM) of Ultragenyx Pharmaceutical Inc (RARE)?
The Earnings Per Share (EPS TTM) of Ultragenyx Pharmaceutical Inc (RARE) is -5.83.
